Texas-based Berkshire Biomedical develops a virtual care and prescription drug delivery and management system. The company’s flagship Computerized Oral Prescription Administration (COPA) enables healthcare providers to administer dosage instructions of prescribed, liquid, oral drugs from a mobile app to a handheld device activated by the intended user’s dual biometric authentication (fingerprint and dental recognition).
The COPA system provides a delivery unit for prescribed medicine, virtually manages therapeutic regimens for patients at home or at a clinic, remotely schedules prescribed medication, provides timely reminders to the patient, and releases prescribed medications to the mouthpiece of the handheld device. The system also transmits real-time event data to a cloud platform for storage and analysis through a mobile-enabled database management system (DBMS).
In January 2021, Berkshire Biomedical raised USD 3 million to commercialize its COPA system that was under US Food & Drug Administration as of February 2021. The company expects to receive regulatory clearance in Q3 2021.
By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.